Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, settembre 12
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Summit Therapeutics Inc
SMMT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$17.55
0.55
3.24%
In chiusura: Sep 11, 5:00 PM EST
$17.70
0.15
0.85%
Post-mercato: 7:58 PM EST
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Summit Therapeutics Financials
Summit Therapeutics (SMMT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.
Vandana Singh
PRO
Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.28) by 32.14 percent. This is a 58.33 percent decrease over losses of $(0.12) per share
Benzinga Newsdesk
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
Evette Mitkov
PRO
Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate
Benzinga Newsdesk
Nasdaq 100 Tops Records As Iran Ceasefire Extends, GE Vernova Soars 13%: Stock Market Today
Tech stocks brushed new record highs during midday Wednesday, as a fresh wave of blockbuster corporate earnings propelled mega-cap technology and speculative names higher.
Piero Cingari
Privacy Manager